BMY up 3% after Q3 earnings: should you buy, sell or hold the stock?
FROM THE WIRE · FINANCE.YAHOO.COM
Bristol Myers Squibb BMY shares gained 3% following the company's third-quarter earnings release, closing at $62.48 on Oct. 30, as investors responded positively to its better-than-expected results. Strong performance from BMY's Growth Portfolio was the primary driver of the…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe pharma stock rose after a better-than-expected quarter driven by newer products.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01BMY shares gained 3% following the third-quarter earnings release, closing at 62.48 dollars on Oct. 30.
- 02Strong performance from the Growth Portfolio was the primary driver of the earnings and revenue beat.
- 03Shares of the company declined 4.5% in the past three months, underperforming the sector and the S&P 500.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets